July 11th- Prof. Thomas Cluzeau- Overall Survival and Duration of Transfusion Independence for First-Line ESA-Naive Patients With Lower-Risk Myelodysplastic Syndromes Treated With Luspatercept vs Epoetin Alfa in the COMMANDS Trial